TerminatedPhase 2NCT05987176
Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
Studying Gastroenteropancreatic neuroendocrine neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Imperial College London
- Principal Investigator
- Andrea Frilling, ProfImperial College London
- Intervention
- Lutathera(drug)
- Enrollment
- 1 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2025
Study locations (1)
- Imperial College Healthcare NHS Trust, London, United Kingdom
Collaborators
The Taylor Family 2010 Charitable Trust · Novartis/AAA
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05987176 on ClinicalTrials.govOther trials for Gastroenteropancreatic neuroendocrine neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06356467Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENsIRCCS San Raffaele
- ACTIVE NOT RECRUITINGPHASE1NCT05262556NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine CarcinomasAmr Mohamed MD
- ACTIVE NOT RECRUITINGPHASE1NCT04750954Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNANCT03012789Surgical Intervention and the NETestWren Laboratories LLC
See all trials for Gastroenteropancreatic neuroendocrine neoplasm →